Showing results (261-270 of 450) with videos related to
Sort By:
Pageof 45
Plos One|November 26, 2015
Characterisation of the Candida albicans Phosphopantetheinyl Transferase Ppt2 as a Potential Antifungal Drug TargetKatharine S Dobb, Sarah J Kaye, Nicola Beckmann, et al.Journal of Pediatric Gastroenterology and Nutrition|July 6, 2010
Effect of Kasai procedure on hepatic outcome in Alagille syndromeAdam J Kaye, Elizabeth B Rand, Pedro S Munoz, et al.Science (New York, N.Y.)|July 15, 1988
Abnormalities in structure and expression of the human retinoblastoma gene in SCLCJ W Harbour, S L Lai, J Whang-Peng, et al.Journal of the National Cancer Institute|December 20, 1995
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesotheliomaR A Kratzke, G A Otterson, C E Lincoln, et al.Biorxiv : the Preprint Server for Biology|March 11, 2024
PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancerSajid Khan, Lin Cao, Janet Wiegand, et al.Clinical Radiology|July 2, 2003
Metastases to the breast revisited: radiological-histopathological correlationL Bartella, J Kaye, N M Perry, et al.International Journal of Cancer|October 9, 1995
CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell linesM J Kelley, G A Otterson, F J Kaye, et al.The Journal of Trauma|July 12, 2007
Emergency department length of stay: a major risk factor for pneumonia in intubated blunt trauma patientsBrendan G Carr, Adam J Kaye, Douglas J Wiebe, et al.Ochsner Journal|July 11, 2012
Sleep physiology, abnormal States, and therapeutic interventionsAlvah T Wickboldt, Alex F Bowen, Aaron J Kaye, et al.Cells|March 27, 2024
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung CancerSajid Khan, Lin Cao, Janet Wiegand, et al.Pageof 45